Advancing drug discovery with Deloitte’s Atlas AI™ has been saved
Article
Advancing drug discovery with Deloitte’s Atlas AI™
Deloitte and Google Cloud share new insights on AI in drug discovery
Discovering a new drug can typically span over a decade and involve significant financial investment. Learn how new artificial intelligence-enabled solutions from Deloitte and Google Cloud can help researchers address redundant experimental efforts and navigate copious data silos to find a faster, more efficient path to breakthroughs.
Data harmonization and connectivity in AI drug discovery
A new perspective on data harmonization, connectivity, and AI models for drug discovery explores how artificial intelligence (AI) and large language models (LLMs)—introduced as Atlas AI in collaboration with Google—can enable new approaches to use AI in drug discovery. Read the report to learn:
- The difference between target-based and phenotypic drug discovery
- Why the most readily exploitable drug targets have already been identified
- How data connectivity and harmonization can help reduce experiments and save time
Shaping the future of AI in drug discovery
The paper also details how organizations can use Atlas AI to make AI drug discovery more efficient over time and reverse the trend of increasing costs and timelines by:
- Reducing time needed to develop new hypotheses for experimental design
- Removing data silos and redundancy of wet lab experiments
- Creating loops across data and scientific workflows
“The ultimate test of any predictive model's utility lies in its verification through empirical evidence. In the context of biology, this necessitates a close integration between AI-driven predictions and wet lab experimentation.”
— Daniel Ferrante, PhD, A new perspective on data harmonization, connectivity, and AI models for drug discovery
Additional Resources
${column1-large-text}
A closer look at Atlas AI
Learn how Deloitte’s Atlas AI leverages the power of knowledge graphs and Generative AI to help you turn the huge growth of data into a strength and enable a modern approach to pharmaceutical R&D.
${column2-large-text}
The Deloitte and Google Cloud alliance
Learn how Deloitte can help you connect the innovation of the Google Cloud ecosystem in ways that allow you to unlock outsized business value and new competitive opportunities.
${column3-large-text}
${column3-title}
${column3-text}
${column4-large-text}
${column4-title}
${column4-text}
Our leaders
Daniel Ferrante, PhD
Managing Director and RnD Innovation Leader
Deloitte Consulting LLP
+1 212 653 2859
Annabel Romero Hernandez, PhD
Specialist Leader
Deloitte Consulting LLP
+1 914 479 9458
${fourth-leader-name}
${fourth-leader-title}
${fourth-leader-additional-info}
Recommendations
Life sciences research and development insights
Reshaping R&D innovation. Data-driven. Digitally enabled. Patient-focused.
Generative AI could help accelerate clinical development
Three processes that could be improved with generative AI.
